Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis - PubMed (original) (raw)

Comparative Study

. 2015 Oct;45(10):1263-70.

doi: 10.1007/s00595-014-1071-5. Epub 2014 Nov 22.

Affiliations

• PMID: 25412984
• DOI: 10.1007/s00595-014-1071-5

Comparative Study

Experience with perioperative pirfenidone for lung cancer surgery in patients with idiopathic pulmonary fibrosis

Takekazu Iwata et al. Surg Today. 2015 Oct.

Abstract

Purpose: Idiopathic pulmonary fibrosis (IPF) is a progressive diffuse lung disease associated with an increased risk of lung cancer. Patients with IPF sometimes develop a life-threatening acute exacerbation of IPF (AE-IPF) after lung cancer surgery. In this retrospective study, pirfenidone, an antifibrotic agent, was perioperatively administered to IPF patients with lung cancer with the aim of preventing postoperative AE-IPF, and the feasibility and clinical outcomes were investigated.

Methods: Twelve IPF patients with concomitant lung cancer who received perioperative pirfenidone treatment (PPT) for lung cancer surgery were retrospectively investigated. Sixteen IPF patients undergoing lung cancer surgery without PPT were analyzed as historical controls.

Results: Compared to the controls, the PPT patients had a more severely impaired preoperative pulmonary function and a larger number of limited pulmonary resections. There was a significant preoperative decrease in the serum KL-6 levels of the PPT patients. No severe pirfenidone-related complications or IPF-related events occurred in the PPT patients, while six control patients developed AE-IPF (P = 0.0167). A quantitative histopathological evaluation of resected lung specimens found that tissue changes associated with IPF were significantly fewer in the PPT patients (P = 0.021).

Conclusions: PPT is a feasible perioperative treatment for IPF patients with lung cancer. Its effectiveness in preventing postoperative AE-IPF thus warrants prospective verification.

Keywords: Acute exacerbation; Idiopathic pulmonary fibrosis; Lung cancer; Pirfenidone; Surgery.

PubMed Disclaimer

Similar articles

• Effect of Perioperative Pirfenidone Treatment in Lung Cancer Patients With Idiopathic Pulmonary Fibrosis.
  Iwata T, Yoshida S, Fujiwara T, Wada H, Nakajima T, Suzuki H, Yoshino I. Iwata T, et al. Ann Thorac Surg. 2016 Dec;102(6):1905-1910. doi: 10.1016/j.athoracsur.2016.05.094. Epub 2016 Aug 18. Ann Thorac Surg. 2016. PMID: 27546601
• Perioperative pirfenidone treatment as prophylaxis against acute exacerbation of idiopathic pulmonary fibrosis: a single-center analysis.
  Sekihara K, Aokage K, Miyoshi T, Tane K, Ishii G, Tsuboi M. Sekihara K, et al. Surg Today. 2020 Aug;50(8):905-911. doi: 10.1007/s00595-020-01978-9. Epub 2020 Mar 6. Surg Today. 2020. PMID: 32144483
• Perioperative pirfenidone treatment for lung cancer patients with idiopathic pulmonary fibrosis.
  Kanayama M, Mori M, Matsumiya H, Taira A, Shinohara S, Kuwata T, Imanishi N, Yoneda K, Kuroda K, Tanaka F. Kanayama M, et al. Surg Today. 2020 May;50(5):469-474. doi: 10.1007/s00595-019-01923-5. Epub 2019 Nov 26. Surg Today. 2020. PMID: 31773277
• Perioperative management of hepatectomy in patients with interstitial pneumonia: a report of three cases and a literature review.
  Kubo N, Araki K, Yamanaka T, Hoshino K, Ishii N, Tsukagoshi M, Igarashi T, Watanabe A, Hirai K, Saitoh F, Kuwano H, Shirabe K. Kubo N, et al. Surg Today. 2017 Oct;47(10):1173-1179. doi: 10.1007/s00595-017-1489-7. Epub 2017 Mar 1. Surg Today. 2017. PMID: 28251374 Review.
• Surgical treatment for primary lung cancer combined with idiopathic pulmonary fibrosis.
  Watanabe A, Miyajima M, Mishina T, Nakazawa J, Harada R, Kawaharada N, Higami T. Watanabe A, et al. Gen Thorac Cardiovasc Surg. 2013 May;61(5):254-61. doi: 10.1007/s11748-012-0180-6. Epub 2012 Nov 28. Gen Thorac Cardiovasc Surg. 2013. PMID: 23188513 Review.

Cited by

• Treatment of idiopathic pulmonary fibrosis and progressive pulmonary fibrosis: A position statement from the Thoracic Society of Australia and New Zealand 2023 revision.
  Mackintosh JA, Keir G, Troy LK, Holland AE, Grainge C, Chambers DC, Sandford D, Jo HE, Glaspole I, Wilsher M, Goh NSL, Reynolds PN, Chapman S, Mutsaers SE, de Boer S, Webster S, Moodley Y, Corte TJ. Mackintosh JA, et al. Respirology. 2024 Feb;29(2):105-135. doi: 10.1111/resp.14656. Epub 2024 Jan 11. Respirology. 2024. PMID: 38211978 Free PMC article.
• Meta-analysis: clinical features and treatments of lung cancer in combined pulmonary fibrosis and emphysema.
  Zhou J, Jiang Y. Zhou J, et al. Sarcoidosis Vasc Diffuse Lung Dis. 2023 Dec 20;40(4):e2023045. doi: 10.36141/svdld.v40i4.14433. Sarcoidosis Vasc Diffuse Lung Dis. 2023. PMID: 38126502 Free PMC article.
• Idiopathic pulmonary fibrosis and lung cancer: future directions and challenges.
  Abu Qubo A, Numan J, Snijder J, Padilla M, Austin JHM, Capaccione KM, Pernia M, Bustamante J, O'Connor T, Salvatore MM. Abu Qubo A, et al. Breathe (Sheff). 2022 Dec;18(4):220147. doi: 10.1183/20734735.0147-2022. Epub 2023 Jan 10. Breathe (Sheff). 2022. PMID: 36865932 Free PMC article. Review.
• Pirfenidone inhibits cell fibrosis in connective tissue disease-associated interstitial lung disease by targeting the TNF-α/STAT3/KL6 pathway.
  Zuo Y, Liu J, Xu H, Li Y, Tao R, Zhang Z. Zuo Y, et al. J Thorac Dis. 2022 Jun;14(6):2089-2102. doi: 10.21037/jtd-22-41. J Thorac Dis. 2022. PMID: 35813760 Free PMC article.

References

1. 1. Thorax. 2006 Nov;61(11):980-5 - PubMed
2. 1. J Thorac Oncol. 2011 Jul;6(7):1242-6 - PubMed
3. 1. N Engl J Med. 2014 May 29;370(22):2083-92 - PubMed
4. 1. Surg Today. 2014 Mar;44(3):494-8 - PubMed
5. 1. Gen Thorac Cardiovasc Surg. 2013 Oct;61(10):578-607 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Springer

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program